These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1682458)

  • 21. Effect of permeability enhancers on paracellular permeability of acyclovir.
    Ates M; Kaynak MS; Sahin S
    J Pharm Pharmacol; 2016 Jun; 68(6):781-90. PubMed ID: 27061718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
    de Miranda P; Burnette TC
    Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ageing on the oral absorption of D-xylose in rats.
    Yuasa H; Kawanishi K; Watanabe J
    J Pharm Pharmacol; 1995 May; 47(5):373-8. PubMed ID: 7494185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.
    Burnette TC; de Miranda P
    Drug Metab Dispos; 1994; 22(1):60-4. PubMed ID: 8149891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents.
    Ohtsu Y; Susaki Y; Noguchi K
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):693-706. PubMed ID: 29748821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir.
    Gourdon B; Chemin C; Moreau A; Arnauld T; Baumy P; Cisternino S; Péan JM; Declèves X
    Int J Pharm; 2017 Aug; 529(1-2):357-370. PubMed ID: 28705621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of absorption enhancers on nasal absorption of acyclovir.
    Chavanpatil MD; Vavia PR
    Eur J Pharm Biopharm; 2004 May; 57(3):483-7. PubMed ID: 15093597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of the gastrointestinal absorption of morphine in rats.
    Tan T; Kuramoto M; Takahashi T; Nakamura H; Nakanishi Y; Imasato Y; Yoshimura H
    Chem Pharm Bull (Tokyo); 1989 Jan; 37(1):168-73. PubMed ID: 2720846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers.
    Lin H; Tian Y; Tian JX; Zhang ZJ; Mao GG
    Arzneimittelforschung; 2010; 60(3):162-7. PubMed ID: 20422949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similarity in the linear and non-linear oral absorption of drugs between human and rat.
    Chiou WL; Ma C; Chung SM; Wu TC; Jeong HY
    Int J Clin Pharmacol Ther; 2000 Nov; 38(11):532-9. PubMed ID: 11097145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?
    Srinivas NR
    Pharm Res; 2016 Mar; 33(3):543-7. PubMed ID: 26474764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanism of oral absorption of panaxnotoginseng saponins].
    Han M; Han LM; Wang QS; Bai ZH; Fang XL
    Yao Xue Xue Bao; 2006 Jun; 41(6):498-505. PubMed ID: 16927822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.
    Tod M; Lokiec F; Bidault R; De Bony F; Petitjean O; Aujard Y
    Antimicrob Agents Chemother; 2001 Jan; 45(1):150-7. PubMed ID: 11120958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-β-cyclodextrin.
    Nair AB; Attimarad M; Al-Dhubiab BE; Wadhwa J; Harsha S; Ahmed M
    Drug Deliv; 2014 Nov; 21(7):540-7. PubMed ID: 24215288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel food drug interaction mechanism involving acyclovir, chitosan and endogenous mucus.
    García MA; Hensler G; Al-Gousous J; Pielenhofer J; Wagner M; Lennernäs H; Langguth P
    Drug Metab Pharmacokinet; 2023 Apr; 49():100491. PubMed ID: 36805824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of acyclovir after intravenous and oral administration.
    de Miranda P; Blum MR
    J Antimicrob Chemother; 1983 Sep; 12 Suppl B():29-37. PubMed ID: 6355048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro.
    Hostetler KY; Beadle JR; Kini GD; Gardner MF; Wright KN; Wu TH; Korba BA
    Biochem Pharmacol; 1997 Jun; 53(12):1815-22. PubMed ID: 9256156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced transdermal delivery of acyclovir sodium via elastic liposomes.
    Jain SK; Gupta Y; Jain A; Rai K
    Drug Deliv; 2008; 15(3):141-7. PubMed ID: 18379926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.
    Merzlikine A; Rotter C; Rago B; Poe J; Christoffersen C; Thomas VH; Troutman M; El-Kattan A
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1082-91. PubMed ID: 19294548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose dependency in the oral bioavailability of an organic cation model, tributylmethyl ammonium (TBuMA), in rats: association with the saturation of efflux by the P-gp system on the apical membrane of the intestinal epithelium.
    Kim MK; Han L; Choi MK; Han YH; Kim DD; Chung SJ; Shim CK
    J Pharm Sci; 2005 Dec; 94(12):2644-55. PubMed ID: 16258993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.